Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Biogen Inc. Common Stock

BIIB

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Last trade $249.28
Day change -$2.37 (-0.94%)
Day range $247.03 – $259.04
Volume 397,749
Market cap $37.20B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$37.2B
Price / earnings
107.05×
Price / book
1.97×
Price / sales
3.61×
EV / sales
4.23×
EV / EBITDA
22.58×

Profitability

Earnings per share
$2.35
Return on assets
1.08%
Return on equity
1.84%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.41×
Current ratio
1.95×
Quick ratio
1.37×
Cash ratio
0.33×

Cash flow

Price / cash flow
16.55×
Price / free cash flow
17.96×
Free cash flow
$2.07B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BIIB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$2.8B$2.74B$2.48B$2.28B$2.53B$2.65B$2.43B$2.45B
Cost of revenue$748.4M$776.9M$661M$495.5M$674.4M$605M$629.3M$583.5M
Gross profit$2.06B$1.96B$1.82B$1.78B$1.86B$2.04B$1.8B$1.87B
Selling, general and administrative$752M$709.7M$607.3M$682.5M$594.8M$583.8M$572.5M$680M
Research and development$857.8M$693.6M$573M$731.8M$438.2M$445.6M$634.8M$532.3M
Total operating expenses$1.93B$1.81B$1.42B$1.69B$1.26B$1.25B$1.42B$1.43B
Operating income$128.8M$150.9M$397.4M$98.4M$597M$792.7M$379.6M$441.4M
Interest expense$0-$82.3M$0$0$0-$72.6M$0$0
Income before taxes-$9M$132.4M$377.7M-$56M$557.3M$744M$311.2M$291.5M
Income taxes$11.6M$34.9M$58.2M-$7.1M$90.8M$109.2M$70.7M$24.8M
Net income-$20.6M$97.5M$319.5M-$48.9M$466.5M$634.8M$240.5M$266.7M
Net income attributable to common shareholders-$20.6M$97.5M$319.5M-$48.9M$466.5M$634.8M$240.5M$266.7M
EBITDA$436.4M$554.9M$609.7M$329.7M$806.6M$999.5M$598.1M$606.9M
Basic earnings per share-$0.14$0.66$2.17-$0.33$3.18$4.33$1.65$1.83
Diluted earnings per share-$0.14$0.66$2.15-$0.33$3.17$4.33$1.64$1.83

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

GlobeNewswire Inc.

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

Eisai and Biogen announced five-year data from the Clarity AD trial showing lecanemab (LEQEMBI) reduced relative risk of disease progression by 36% compared to natural history data. Over 60% of patients with low tau showed improvement or stability in cognitive function and daily living activities at five years, with benefits continuing to accrue over time. The safety profile remained consistent with no new findings observed.

The Motley Fool

Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?

State Street's XPH (SPDR S&P Pharmaceuticals ETF) is recommended over Invesco's PBE (Biotechnology & Genome ETF) for long-term investors due to its lower expense ratio (0.35% vs 0.59%), broader diversification with 61 holdings, lower beta, and better recent 1-year performance (38.6% vs 33.2%). While PBE offers a higher dividend yield (1.3% vs 0.4%), XPH's exposure to pharmaceutical acquisitions and lower costs make it more suitable for most long-term investors.

The Motley Fool

Better Biotech ETF: First Trust's FBT vs. Invesco's PBE

First Trust's FBT and Invesco's PBE are compared as primary vehicles for biotech sector exposure. FBT offers lower fees (0.55% vs 0.59%), higher AUM ($3.0B vs $438M), and stronger 1-year returns (35.7% vs 28.1%), while PBE provides dividend income and uses a multi-factor quantitative approach. The choice depends on investor priorities regarding cost, liquidity, and investment strategy.

The Motley Fool

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.